SIBO causes inflammation both in the gut and systemically and is notoriously difficult to treat, with high relapse rates, so finding new treatment protocols for SIBO is hugely beneficial.
The ancient wisdom of Hippocrates who believed that ‘all disease begins in the gut’ is being validated by modern science, with poor gastrointestinal (GIT) health linked to an increasing number of diseases.
With the emergence of antibiotic resistance, one goal of research scientists has been to understand through which medium bacteria communicate, and how we may inhibit this conversation.
Abdominal pain is one of the most common diagnoses in hospitalised children and the leading symptom in child and adolescent GIT diseases. It is also a common symptom of SIBO.
Theories surrounding when is the best time to take a probiotic supplement in order to yield the best, actionable benefits has long been a source of contention. One recently published study has highlighted that there seems to be little difference to the measurable outcomes.
What are the differences in gut bacteria from an obese person to a lean person? Scientists are starting to explore this further.
From 25-50% of women have at least one episode of UTIs in their lives, and of these, 27% have a relapse during the six months following the first infection, while approximately 3% have two relapses during the same period.
For the past several years I have been writing and lecturing about the relationship between Alzheimer’s disease and changes in the gut bacteria.